BFAG
CCCC icon

Blackston Financial Advisory Group’s C4 Therapeutics CCCC Stock Holding History

Blackston Financial Advisory Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$26.3K – 107
2026
Q1 		$26.3K Hold
10,000
– – 0.02% 106
2025
Q4 		$19.1K Buy
+10,000
New +$23.7K 0.01% 102

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Blackston Financial Advisory Group's CCCC Position: Q2 2026 in Review

Blackston Financial Advisory Group sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 10,000 shares — an estimated $26.3K sold.

Blackston Financial Advisory Group first reported a position in CCCC in Q4 2025 and held it in 2 quarters. The position peaked at $26.3K in Q1 2026. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Blackston Financial Advisory Group reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Blackston Financial Advisory Group sold 10,000 C4 Therapeutics shares in Q2 2026, an estimated $26.3K.
  • Blackston Financial Advisory Group first reported a position in C4 Therapeutics in Q4 2025 and held it in 2 quarters.
  • Blackston Financial Advisory Group's C4 Therapeutics position peaked at $26.3K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Blackston Financial Advisory Group's 13F filing for Q2 2026, filed 14 Aug 2026.